Anlotinib and Benmelstobart
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pheochromocytoma
Conditions
Pheochromocytoma
Trial Timeline
May 1, 2025 → May 28, 2027
NCT ID
NCT06429397About Anlotinib and Benmelstobart
Anlotinib and Benmelstobart is a phase 2 stage product being developed by Sun Pharmaceutical for Pheochromocytoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06429397. Target conditions include Pheochromocytoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06429397 | Phase 2 | Recruiting |
Competing Products
4 competing products in Pheochromocytoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Belzutifan | Merck | Phase 2 | 52 |
| Axitinib | Pfizer | Phase 2 | 51 |
| ONC206 + ONC206: Dose 1 + ONC206: Dose 2 | Jazz Pharmaceuticals | Phase 2 | 49 |
| Phenoxybenzamine + Doxazosin | Atrium Therapeutics | Approved | 77 |
Other Products from Sun Pharmaceutical
Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85